Formulation and Production of a Novel Pharmaceutical Substance for Treatment of Infected Wounds - a Chitosan Chymopsin Complexстатья
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 4 января 2019 г.
Аннотация:Abstract
Wound infection represent a serious threat to wounded patients all over the world. Untreated wounds may result in bacterial wound infections,
such as gas gangrene and tetanus. These in turn may lead to long term disabilities, chronic wound or bone infection, and, ultimately, death.
Appropriate management of infected wounds is important to reduce the likelihood of life-threatening complications.
Chitosan chymopsin complex (CCC) is a novel pharmaceutical substance consisting of chymopsin (a combination of two proteolytic enzymes:
trypsin and chymotrypsin) and acid-soluble chitosan (a natural high molecular weight polysaccharide). This substance, either alone or together
with antiseptic and/or anesthetic agents, can be used in treatment of infected wounds of different etiology.
Synthesis, and production of active pharmaceutical ingredients (API) using biotechnological methods are the most demanding and costly
stages of drug manufacturing. Therefore, a thoughtfully performed formulation can significantly reduce production costs, make manufacturing
less labour-intensive, and, of course, improve API performance and quality.
The paper describes the process of formulation of a novel API which possesses complex therapeutical activity, allows for faster wound healing
and effective clearance of wound surface from pus and necrotic debris.
Keywords: active pharmaceutical ingredient, chitin deacetylation, chitosan chymopsin complex (ССС), crab hepatopancreas, infected wounds treatment,
polyelectrolyte complex (PEC), proteolytic complex (PC), proteolytic unit (PU).